中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
12期
55-57
,共3页
黄楚泉%张圳锐%蔡立泓%郭正端
黃楚泉%張圳銳%蔡立泓%郭正耑
황초천%장수예%채립홍%곽정단
偏头痛%盐酸洛美利嗪%钙通道拮抗剂%疗效%安全性
偏頭痛%鹽痠洛美利嗪%鈣通道拮抗劑%療效%安全性
편두통%염산락미리진%개통도길항제%료효%안전성
Migraine%Lomerizine hydrochloride tablet%Calcium channels antagonist%Efficacy%Security
目的 评价国产盐酸洛美利嗪治疗偏头痛的临床疗效及安全性.方法 采取随机、双盲、安慰剂对照进行观察,将入选的50例患者随机分为盐酸洛美利嗪组(A组,25例,口服盐酸洛美利嗪片5 mg,2次/d)及对照组(B组,25例,口服安慰剂,2次/d),疗程均为12周.以头痛发作频率为主要评定指标,发作持续时间、程度、伴随症状及头痛综合评分为次要评定指标,并记录不良反应.结果 ①A组治疗第4、8、12、16周末时,头痛发作频率、头痛持续时间、头痛程度、伴随症状及头痛综合评分较B组显著降低(P＜0.01)；②A组总有效率为96.0％,显著优于B组的16.0％ (P＜0.01).两组治疗期间均无严重不良反应.结论 国产盐酸洛美利嗪预防性治疗偏头痛安全、有效,而且停药后仍有一定时间的疗效.
目的 評價國產鹽痠洛美利嗪治療偏頭痛的臨床療效及安全性.方法 採取隨機、雙盲、安慰劑對照進行觀察,將入選的50例患者隨機分為鹽痠洛美利嗪組(A組,25例,口服鹽痠洛美利嗪片5 mg,2次/d)及對照組(B組,25例,口服安慰劑,2次/d),療程均為12週.以頭痛髮作頻率為主要評定指標,髮作持續時間、程度、伴隨癥狀及頭痛綜閤評分為次要評定指標,併記錄不良反應.結果 ①A組治療第4、8、12、16週末時,頭痛髮作頻率、頭痛持續時間、頭痛程度、伴隨癥狀及頭痛綜閤評分較B組顯著降低(P＜0.01)；②A組總有效率為96.0％,顯著優于B組的16.0％ (P＜0.01).兩組治療期間均無嚴重不良反應.結論 國產鹽痠洛美利嗪預防性治療偏頭痛安全、有效,而且停藥後仍有一定時間的療效.
목적 평개국산염산락미리진치료편두통적림상료효급안전성.방법 채취수궤、쌍맹、안위제대조진행관찰,장입선적50례환자수궤분위염산락미리진조(A조,25례,구복염산락미리진편5 mg,2차/d)급대조조(B조,25례,구복안위제,2차/d),료정균위12주.이두통발작빈솔위주요평정지표,발작지속시간、정도、반수증상급두통종합평분위차요평정지표,병기록불량반응.결과 ①A조치료제4、8、12、16주말시,두통발작빈솔、두통지속시간、두통정도、반수증상급두통종합평분교B조현저강저(P＜0.01)；②A조총유효솔위96.0％,현저우우B조적16.0％ (P＜0.01).량조치료기간균무엄중불량반응.결론 국산염산락미리진예방성치료편두통안전、유효,이차정약후잉유일정시간적료효.
Objective To study the efficacy and safety of lomerizine hydrochloride for treating migraine.Methods Fifty patients with migraine were randomly divided into lomerizine hydrochloride group (group A,25 cases) and control group (group B,25 cases),and the patients were treated with lomerizine hydrochloride or placebo orally respectively.The treatment were 12 weeks.The frequency of migraine attacks as the main assessment indicators,and attack duration,extent,accompanied by symptoms and headache composite score for secondary assessmentindicators,and recorded adverse reactions.Results ① The 4,8,12 and 16 weeks after treatment,the headache attack frequency,headache duration,headache extent,associated symptom and headache composite in group A were decreased significantly compared with group B (P all ＜0.01).②The total effective rates of group A and group B were 96.0％ and 16.0％ respectively (P ＜ 0.01).No serious adverse reaction occured in both groups.Conclusions Lomerizine hydrochloride is effective and safe for preventive treatment of migraine and there is still a certain period of time effect after stop medication.
